Reply to correspondence on "Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets"

In the study by Shi and colleagues [3], among the 28 circulating complement components that they evaluated, only a significant causal association between the C8 gamma chain and MASLD via the inverse-variance weighted MR method has been reported, and that association was not significant by the weighted median method. Comprehensive evaluation via the MR method in diverse populations and clinical validation will enable us to bridge the gap between understanding the mechanisms involving complement proteins in liver diseases and offering new treatment options or diagnostic and prognostic biomarkers. Conflicts of Interest J.D.Y. provides a consulting service for AstraZeneca, Eisai, Exact Sciences, Exelixis, Fujifilm Medical Sciences, and Gilead Sciences.